Skip to main content
AMC Holdings and MGC Pharmaceuticals execute binding supply agreement for U.S. Market
Close Search
Menu
Home
About
Products
News
Contact
Buy Now
News
Filter
News
$24Million AMC-MGC Distribution Agreement Announced
Disease management of intractable conditions, like Refractory Epilepsy and Dementia, as well as the recent…
Phase 3 Clinical Trial Launched for Covid 19 Treatment: CimetrA
"MGC Pharmaceuticals Ltd. said Monday that it has started the Phase 3 clinical trial for CimetrA.…
Phase IIb Clinical Trial at Notre Dame for Alzheimers Treatment: CogniCann
CogniCann Phase II clinical trial The Phase II clinical trial at the University of Notre…
CannEpil Refractory Epilepsy Drug Approved in Ireland
European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has announced that its epilepsy drug, CannEpil, will now be fully…
Clinical Trials Progress in Israel, Australia and Brazil
MGC Pharmaceuticals Ltd’s (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) major clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021…
Patent Application Submitted For Covid-19 Treatment
MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical…
Close Menu
AMC Holdings and MGC Pharmaceuticals execute binding supply agreement for U.S. Market
Home
About
Products
News
Contact
Buy Now
